Mizuno Aki, Lolachi Sanaz, Pernet Alain
Service de médecine interne générale, Hôpital de La Tour, Avenue J.-D. Maillard 3, 1217 Meyrin.
Unité de diabétologie, Hôpital de La Tour, Avenue J.-D. Maillard 3, 1217 Meyrin.
Rev Med Suisse. 2017 May 31;13(565):1164-1167.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a new category of oral antidiabetics recently indicated for the treatment of type 2 diabetes. Their mechanism of action (inhibition of renal reabsorption of glucose) and the fact that they do not induce hypoglycemia (as monotherapy) make their clinical use interesting. Various adverse events have however been reported regarding these drugs with the euglycemic ketoacidosis being the most serious. In this article we aim to review the possible mechanism of this side effect and recommendations for use of SGLT2 inhibitors by means of a case report.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一类新型口服抗糖尿病药物，最近被用于治疗2型糖尿病。其作用机制（抑制肾脏对葡萄糖的重吸收）以及不会引起低血糖（作为单一疗法）这一事实，使得它们在临床上具有应用价值。然而，关于这些药物已经报道了各种不良事件，其中正常血糖性酮症酸中毒最为严重。在本文中，我们旨在通过一例病例报告来综述这种副作用的可能机制以及使用SGLT2抑制剂的建议。
